{
    "name": "sodium iodide I-131",
    "comment": "Rx",
    "other_names": [
        "Hicon"
    ],
    "classes": [
        "Antithyroid Agents",
        "Radiopharmaceuticals"
    ],
    "source": "https://reference.medscape.com/drug/hicon-sodium-iodide-i-131-999924",
    "pregnancy": {
        "common": [
            "Contraindicated in pregnancy because fetal exposure can lead to neonatal hypothyroidism, which in some cases is severe and irreversible",
            "Data from published literature describe reports of neonatal thyroid abnormalities after fetal exposure; including agenesis of thyroid and hypothyroidism; no animal reproductive studies have been conducted",
            "A fetus exposed to sodium iodide I 131 can develop neonatal hypothyroidism; delay in diagnosis of neonatal hypothyroidism after exposure to sodium iodide I 131 in utero can result in severe sequelae such as cognitive impairment and delayed bone age; monitor thyroid function in any infant born after in utero exposure to sodium iodide I 131"
        ],
        "specific": [
            {
                "type": "Pregnancy Testing",
                "description": [
                    "Obtain a pregnancy test in females of reproductive potential and verify absence of pregnancy within 24 hours prior to administration of treatment"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Advise females and males of reproductive potential to use effective contraception during treatment and for at least six months after last dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Females: Fertility may be impaired with treatment; transient amenorrhea and ovarian insufficiency observed after sodium iodide I 131; therapy in females; the literature describes reports of transient menstrual cycle irregularities, including amenorrhea, and ovarian failure in females treated with cumulative doses of 1,000 MBq to 59,000 MBq (27 mCi to 1,595 mCi) sodium iodide I 131; in a published literature analysis, the effects on fertility occurred in up to 30% of women treated with sodium iodide I 131, and may resolve 12 months after treatment.",
                    "Males: Fertility may be impaired with treatment; discuss sperm banking for males who are expected to receive a high cumulative dose of sodium iodide I 131; transient dose-related impairment of testicular function after sodium iodide I 131 therapy has been reported in the published literature; the literature describes reports of males treated with sodium iodide I 131 at doses of 370 MBq to 22,000 MBq (10 mCi to 595 mCi) resulting in transiently impaired testicular function (including spermatogenesis); the risk of persistent testicular dysfunction increases after administration of repeated or high cumulative radioiodide exposure"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Contraindicated in lactating women because sodium iodide I 131 concentrates in breast via increased expression of sodium iodide symporter in breast tissue with lactation and can lead to hypothyroidism in the infant through breastfeeding",
            "Advise lactating women to discontinue breastfeeding at least 6 weeks prior to administration of sodium iodide I 131 to allow sufficient time for involution to occur and to avoid excess concentration of sodium iodide I 131 in breast tissue",
            "Consider administration of drugs to suppress lactation; consider diagnostic scintigraphy before administration of sodium iodide I 131 to assess the persistence of uptake by breast tissue; if sodium iodide I 131 is administered in postpartum period, the lactating mother should not breastfeed the infant",
            "If sodium iodide I 131 is administered postpartum, breastfeeding should not be restarted for the remainder of the postpartum period",
            "Infants exposed to sodium iodide I 131 through breast milk are at risk for development of hypothyroidism because sodium iodide I 131 is distributed into breast milk and may reach concentrations equal to or greater than concentrations in maternal plasma"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Diagnostic use",
                    "description": [
                        "Recent intake of stable iodine in any form, or the use of thyroid or anti-thyroid drugs will affect the uptake of radioiodide"
                    ]
                },
                {
                    "type": "Therapeutic use",
                    "description": [
                        "Consider pre-treatment anti-thyroid medication to help deplete thyroid hormone; discontinue anti-thyroid therapy three days before administration of sodium iodide I 131; consider a beta-blocker pre or post-treatment to minimize risk of hyperthyroidism and thyroid storm",
                        "Instruct patients to follow radiation safety precautions after receiving therapy to minimize radiation contamination of other persons or the environment; patients should avoid close contact with others, especially pregnant women and children, and take care to avoid contamination of other persons or the environment with body fluids",
                        "Thyroiditis may cause gland enlargement resulting in tenderness and swelling of neck, pain on swallowing, sore throat, and cough; which may occur approximately the third day after sodium iodide I 131 administration. Consider management with pain-reliever or anti-inflammatory medications",
                        "Hypersensitivity reactions, including rash and hives reported",
                        "Transplacental passage of sodium iodide I-131 can cause severe and possibly irreversible hypothyroidism in neonates (see Contraindications)",
                        "Transient dose-related impairment of testicular function in men and transient ovarian insufficiency in women has been reported after sodium iodide I 131 therapy; consider sperm banking for men who are anticipated to receive cumulative sodium iodide I 131 doses greater than 19,000 MBq (520 mCi)",
                        "Therapy contributes to a patient’s overall long-term cumulative radiation exposure, which is associated with increased risk of cancer; follow safe handling and administration to minimize radiation exposure to patient and healthcare providers",
                        "Radiation-induced toxicities",
                        "Dose-dependent fatalities (bone marrow suppression, malignancy)",
                        "Dose-dependent hematopoietic suppression which manifests as a transient thrombocytopenia or neutropenia 3-5 weeks following sodium iodide I 131 administrations, may lead to increased susceptibility to infections or bleeding",
                        "Salivary gland toxicity: sialadenitis, xerostomia",
                        "Lacrimal gland toxicity: conjunctivitis, xerophthalmia, and epiphora",
                        "Obtain complete blood count within one month of therapy; if patients show leukopenia or thrombocytopenia, use dosimetry to determine a safe sodium iodide I 131 activity, while delivering less than 2 Gy to bone marrow",
                        "Advise good hydration for one week following sodium iodide I 131 administration and stimulate salivary flow via a sialagogue (e.g. sugar-free candy or gum, pilocarpine, and ascorbic acid) to reduce radiation exposure to salivary glands",
                        "Advise patients to void frequently after administration of radioiodide to enhance excretion"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Concomitant use of bone marrow depressants may enhance depression of the hematopoietic system caused by the use of large doses of sodium iodide I 131",
                        "Certain food or drugs may alter thyroid uptake of sodium iodide I 131 and diminish effectiveness; recent intake of stable iodide in any form, or the use of thyroid or anti-thyroid drugs may diminish thyroid uptake of sodium iodide I 131",
                        "Review the patient’s history, current medications, and recent diagnostic tests prior to administration of sodium iodide I 131",
                        "Advise patients to maintain a low-iodide diet two weeks prior to radioiodide administration and continue for several days during the uptake or imaging process and to discontinue taking amiodarone, topical iodide, kelp, agar, carrageenan, Lugol solution, thionamide medications (propylthiouracil, methimazole, carbimazole), multivitamins containing iodide, natural or synthetic thyroid hormones, iodide containing foods, iodized salt, dairy products, egg yolks, seafood, turkey and liver, before they undergo the procedure for the periods described in the prescribing information"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "levothyroxine will decrease the level or effect of sodium iodide I-131 by  Other (see comment). Contraindicated. Use of thyroid products or iodine before and during treatment with sodium iodide I-131 decreases uptake of sodium iodide I-131 by the thyroid gland"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "liothyronine",
            "description": {
                "common": "liothyronine will decrease the level or effect of sodium iodide I-131 by  Other (see comment). Contraindicated. Use of thyroid products or iodine before and during treatment with sodium iodide I-131 decreases uptake of sodium iodide I-131 by the thyroid gland"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "liotrix",
            "description": {
                "common": "liotrix will decrease the level or effect of sodium iodide I-131 by  Other (see comment). Contraindicated. Use of thyroid products or iodine before and during treatment with sodium iodide I-131 decreases uptake of sodium iodide I-131 by the thyroid gland"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "methimazole",
            "description": {
                "common": "methimazole will decrease the level or effect of sodium iodide I-131 by  Other (see comment). Contraindicated. Discontinue antithyroid medications at least 3-4 days before administering sodium iodide I-131 and do not coadminister; thyroid agents decrease update of sodium iodide I-131 by the thyroid gland"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "potassium iodide",
            "description": {
                "common": "potassium iodide will decrease the level or effect of sodium iodide I-131 by  Other (see comment). Contraindicated. Discontinue iodide-containing supplements at least 10 days before administering sodium iodide I-131 and do not coadminister; thyroid agents decrease uptake of sodium iodide I-131 by the thyroid gland."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "propylthiouracil",
            "description": {
                "common": "propylthiouracil will decrease the level or effect of sodium iodide I-131 by  Other (see comment). Contraindicated. Discontinue antithyroid medications at least 3-4 days before administering sodium iodide I-131 and do not coadminister; thyroid agents decrease update of sodium iodide I-131 by the thyroid gland"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "thyroid desiccated",
            "description": {
                "common": "thyroid desiccated will decrease the level or effect of sodium iodide I-131 by  Other (see comment). Contraindicated. Use of thyroid products or iodine before and during treatment with sodium iodide I-131 decreases uptake of sodium iodide I-131 by the thyroid gland"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will decrease the level or effect of sodium iodide I-131 by  Other (see comment). Modify Therapy/Monitor Closely. Use of stable iodine containing products (eg, amiodarone) before and during treatment with sodium iodide I-131 decreases uptake of sodium iodide I-131 by the thyroid gland"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethiodized oil",
            "description": {
                "common": "ethiodized oil will decrease the level or effect of sodium iodide I-131 by  Other (see comment). Modify Therapy/Monitor Closely. Ethiodized oil remains in the body for several months following administration, and may interfere with thyroid function testing for up to 2 yr;  interferes with radioactive iodine uptake by thyroid tissue for several weeks to months and may impair visualization of thyroid scintigraphy and reduce effectiveness of iodine 131 treatment"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and sodium iodide I-131 both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "Increased radiation accumulation",
            "percent": null
        },
        {
            "name": "Fetal toxicities",
            "percent": null
        },
        {
            "name": "Exposure to breast tissue with lactation",
            "percent": null
        },
        {
            "name": "Transient infertility",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Sialadenitis",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Chest pain and tachycardia",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Iododerma",
            "percent": null
        },
        {
            "name": "itching skin",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "and hives",
            "percent": null
        },
        {
            "name": "Endocrine disorders",
            "percent": null
        },
        {
            "name": "Hypothyroidism",
            "percent": null
        },
        {
            "name": "hyperthyroidism",
            "percent": null
        },
        {
            "name": "thyrotoxic crisis",
            "percent": null
        },
        {
            "name": "hypoparathyroidism",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Local swelling",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system disorders including fatalities",
            "percent": null
        },
        {
            "name": "Radiation sickness",
            "percent": null
        },
        {
            "name": "bone marrow depression",
            "percent": null
        },
        {
            "name": "anemia",
            "percent": null
        },
        {
            "name": "leucopenia",
            "percent": null
        },
        {
            "name": "thrombocytopenia",
            "percent": null
        },
        {
            "name": "and blood dyscrasia",
            "percent": null
        },
        {
            "name": "Neoplasms benign",
            "percent": null
        },
        {
            "name": "malignant and unspecified",
            "percent": null
        },
        {
            "name": "including cysts and polyps",
            "percent": null
        },
        {
            "name": "Leukemia and solid cancers",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Lacrimal gland dysfunction",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Salivary gland dysfunction",
            "percent": null
        },
        {
            "name": "nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "Congenital",
            "percent": null
        },
        {
            "name": "familial and genetic disorders",
            "percent": null
        },
        {
            "name": "Congenital hypothyroidism and chromosomal abnormalities",
            "percent": null
        },
        {
            "name": "Cerebral Edema",
            "percent": null
        },
        {
            "name": "patients with iodine",
            "percent": null
        },
        {
            "name": "avid brain metastases",
            "percent": null
        },
        {
            "name": "Radiation pneumonitis",
            "percent": null
        },
        {
            "name": "patients with iodine",
            "percent": null
        },
        {
            "name": "avid lung metastases",
            "percent": null
        },
        {
            "name": "Pulmonary fibrosis",
            "percent": null
        },
        {
            "name": "patients with iodine",
            "percent": null
        },
        {
            "name": "avid lung metastases",
            "percent": null
        }
    ]
}